Murali Doraiswamy MBBS FRCP is professor of psychiatry and professor in medicine at the Duke University School of Medicine where he is a highly respected physician neuroscientist at the Duke Institute for Brain Sciences. He specializes in the areas of brain health and personalized medicine and leads a clinical trials unit in developing novel personal diagnostics and therapeutics for cognitive enhancement and mental well-being. Prof Doraiswamy has been an advisor to leading government agencies, businesses and advocacy groups. He has served as the chair of the World Economic Forum’s Global Agenda Council on Brain Research and lectured at leading global forums to advance the forefront of neuroscience research. Moreover as co-author of a popular book The Alzheimer’s Action Plan and co-author on more than 350 publications, he has received several awards in recognition of his scientific work and his involvement in pivotal landmark trials that have helped develop many modern neurotherapeutics. Additionally, he is a leading advocate for increasing funding for brain and behavioral research to help address great looming challenges in society posed by modern developments in the 21st century. His research has been featured in media outlets such as BBC, The New York Times, Scientific American, The Wall Street Journal, National Public Radio, CBS Evening news, The Dr Oz Show, Oprah, and TIME. He has appeared in acclaimed documentaries such as (Dis)Honesty: The Truth about Lies and Mysteries of the Brain.
Education and Training
- M.B.B.S., University of Madras (India), 1987
- Genetic Modulations of Morbidity Compression: A Population-Based Study
- Racial and Geographic Disparities in Risk and Survival of Alzheimer's Disease and Related Dementias: Effects of Over/UnderDiagnosis and Disease Severity
- Duke Creating ADRD Researchers for the Next Generation - Stimulating Access to Research in Residency Program (CARiNG-StARR)"
- Metabolomic Signatures for Disease Sub-classification and Target Prioritization in AMP-AD
- Evaluating Effects in the Relationship between Traumatic Brain Injury and Alzheimer's Disease: Epidemiological Determinants, Their Health-Related Causes and the Resulting Disparities
- Gut Liver Brain Biochemical Axis in Alzheimer's Disease
- Metabolic Networks and Pathways Predictive of Sex Differences in AD Risk and Responsiveness to Treatment
- Predicting prebiotic effects on human microbiota, behavior, and cognition.
- Does rifaximin improve cognition in patients with Alzheimer's disease?" using Manufacturer's drug XIFAXAN
- A Clinical-Pathological Study of the Correspondence Between 18F-AV-1451 PET Imaging and Post-Mortem Assessment of Tau Pathology
- Phase 3 Clinical Trial for Agitation in Alzheimer's 15-AVP-786-301
- Phase 3 Clinical Trial for Agitation in Alzheimer's 15-AVP-786-303
- High Resolution Intracortical DTI for Early Detection of Alzheimer¿s Disease
- Effects of Traumatic Brain Injury (TBI) and Post Traumatic Stress Disorder (PTSD) on Alzheimer's Disease (AD) in Veterans Using Imaging and Biomarkers in the AD Neuroimaging Initiative (ADNI) (DoD)
- Effects of Traumatic Brain Injury and Post-Traumatic Stress Disorder on Alzheimer's Disease (AD) in Veterans with Mild Cognitive Impairment (MC) using the Alzheimer's disease neuroimaging initiative (ADNI)
- Effects of Traumatic Brain Injury and Post-Traumatic Stress Disorder and Alzheimer's Disease on Brain Tau in Vietnam Veterans using ADNI